Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

5th Mar 2013 17:33

RNS Number : 3165Z
GlaxoSmithKline PLC
05 March 2013
 



Notification of Transactions of

Directors and Persons Discharging Managerial Responsibility

 

Vesting of Conditional Options granted under GlaxoSmithKline Share Option Plan

 

This notification sets out information relating to the vesting of share options granted in 2009 under the GlaxoSmithKline Share Option Plan (SOP).

 

On 17 February 2009, share options were granted under the SOP to Executive Directors and Persons Discharging Managerial Responsibility (PDMR) at an option price of £11.77, or US $33.42 in the case of an American Depositary Share (ADS). The vesting of options was subject to an EPS performance condition.

 

The performance period for 50% of the options granted in 2009 to Executive Directors and PDMRs commenced on 1 January 2009 and ended on 31 December 2011. As announced last year, these options lapsed in full on 17 February 2012. The remaining 50% of the 2009 option grant was subject to meeting the performance condition over a four-year performance period which commenced on 1 January 2009 and ended on 31 December 2012.

 

The Company did not achieve the EPS performance condition at the end of the four-year performance period to 31 December 2012 and therefore the Remuneration Committee has confirmed that the options conditionally granted to the participants listed below lapsed in full on 1 March 2013.

 

 

 

 

Number of lapsed options over Ordinary Shares/ADS

 

Ordinary Shares

ADS

Dr M Slaoui*

79,375

Mr S Bicknell

25,250

Ms D Connelly

88,750

Mr M Dunoyer

46,250

Mr A Hussain

88,750

Mr W Louv

28,750

Mr D Redfern

35,000

Ms C Thomas

46,250

Mr D Troy

44,375

* Denotes an Executive Director

 

 

The Company, Executive Directors and PDMRs were advised of these transactions on 4 March 2013.

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

V A Whyte

Company Secretary

 

5 March 2013

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSDELFBXXFXBBL

Related Shares:

Glaxosmithkline
FTSE 100 Latest
Value8,632.33
Change89.77